A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer - Trial NCT06110793
Access comprehensive clinical trial information for NCT06110793 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Memorial Sloan Kettering Cancer Center and is currently Not yet recruiting. The study focuses on Metastatic Breast Cancer. Target enrollment is 43 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Memorial Sloan Kettering Cancer Center
Timeline & Enrollment
Phase 1/2
Nov 01, 2023
Nov 01, 2026
Primary Outcome
The number of adverse events and dose-limiting toxicities to find the Recommended Phase 2 Dose (RP2D)
Summary
The purpose of this study is to test whether the combination of lenvatinib, pembrolizumab,
 and fulvestrant is a safe and effective treatment that causes few or mild side effects in
 people with ER+/HER2- metastatic breast cancer.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06110793
Non-Device Trial